Methotrexate in psoriatic polyarthritis. 1994

P D Pigatto, and E Gibelli, and R Ranza, and A Rossetti
Department of Dermatology, University of Milan, Italy.

Methotrexate (MTX) is widely accepted as an effective treatment for psoriasis and chronic polyarthrides. We report data from 54 psoriatic polyarthritis patients (354 encounters) treated with MTX. 65% were males, mean age 47.9 years, mean disease duration 9.8 years for arthritis, 14.2 years for psoriasis. The MTX dose was 10-12.5 mg/week. 32 patients are still on MTX after a mean treatment time of 1.6 years. 22 patients discontinued MTX treatment: 11 felt it to be ineffective, in 6 patients there were side effects, 3 patients obtained remission, while 2 patients underwent surgery. Efficacy was good on the whole: number of swollen and tender joints, global disease activity score, ESR, and CRP all underwent a significant reduction. The intake of symptomatic drugs was reduced in 40%. Psoriasis as assessed with the Psoriasis Activity and Severity Index showed a significant improvement. Our data confirm that MTX is of value in most psoriatic polyarthritis patients (60%). In our experience, this drug, gives the maximum efficacy within 6 months of therapy.

UI MeSH Term Description Entries
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015535 Arthritis, Psoriatic A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor. Psoriasis Arthropathica,Psoriasis, Arthritic,Psoriatic Arthritis,Psoriatic Arthropathy,Arthritic Psoriasis,Arthropathies, Psoriatic,Arthropathy, Psoriatic,Psoriatic Arthropathies

Related Publications

P D Pigatto, and E Gibelli, and R Ranza, and A Rossetti
October 1993, The Journal of rheumatology,
P D Pigatto, and E Gibelli, and R Ranza, and A Rossetti
September 1999, Presse medicale (Paris, France : 1983),
P D Pigatto, and E Gibelli, and R Ranza, and A Rossetti
January 1966, Revue francaise d'etudes cliniques et biologiques,
P D Pigatto, and E Gibelli, and R Ranza, and A Rossetti
April 1958, Zeitschrift fur Rheumaforschung,
P D Pigatto, and E Gibelli, and R Ranza, and A Rossetti
February 1974, Klinicheskaia meditsina,
P D Pigatto, and E Gibelli, and R Ranza, and A Rossetti
October 2002, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,
P D Pigatto, and E Gibelli, and R Ranza, and A Rossetti
August 1963, British medical journal,
P D Pigatto, and E Gibelli, and R Ranza, and A Rossetti
December 1967, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
P D Pigatto, and E Gibelli, and R Ranza, and A Rossetti
January 2013, Bulletin of the Hospital for Joint Disease (2013),
P D Pigatto, and E Gibelli, and R Ranza, and A Rossetti
January 2002, Clinical and experimental rheumatology,
Copied contents to your clipboard!